New hope for muscle stiffness: Once-Daily pill tested in myotonic dystrophy
NCT ID NCT06523400
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 3 trial tests whether a once-daily dose of mexiletine PR can safely reduce muscle stiffness (myotonia) in people with myotonic dystrophy types 1 and 2. About 176 participants will receive either the drug or a placebo for 26 weeks. The main measure is how quickly hand muscles relax after a strong squeeze.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mexiletine PR (prolonged-release granules for oral suspension)
What this could lead to
If successful, this could provide a once-daily treatment option to reduce muscle stiffness and improve daily function for people with myotonic dystrophy.
What could go wrong
This is a Phase 3 trial, but it's still testing a drug that may not work better than placebo. Side effects are possible, and the benefit may be modest or not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOTONIC DYSTROPHY TYPE 1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus University Hospital
RECRUITINGAarhus, Denmark
-
Azienda Ospedaliera Universitaria Policlinico Tor Vergata
RECRUITINGRome, Italy
-
Laboratory for Muscle Diseases and Neuropathies
RECRUITINGLeuven, Belgium
-
Ludug-Maximilians University
RECRUITINGMünchen, Germany
-
Saint George's University Hospitals NHS Foundation Trust
RECRUITINGLondon, United Kingdom
Contact Email: •••••@•••••
-
University College Hospital
RECRUITINGLondon, United Kingdom
-
University Hospital of Madrid
RECRUITINGMadrid, Spain